<\/strong><\/span><\/h4>\n<\/strong><\/span><\/h4>\nAcad. Prof. Univ. Dr. C\u0103lin Giurc\u0103neanu
\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201eCarol Davila\u201d Bucure\u0219ti
\n<\/strong><\/span><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″ locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.7″]<\/p>\n
Simpozion Sanofi: Dupilumab \u2013 primul imunomodulator in Dermatita Atopica<\/span>
Speaker: C\u0103lin Giurc\u0103neanu<\/span><\/p>\nDA este o boala inflamatorie cronica sistemica si nu doar o bolala de piele intermitenta, asa cum era considerata in trecut, caracterizata prin prurit intens si leziuni eczematoase. Adevarata cauza a dermatitei atopice este inflamatia de Tip2\/Th2 iar IL4 si IL13 sunt citokinele cheie implicate in mecanismul imunologic.
Dupixent este prima terapie biologica aprobata pentru tratamentul dermatitei atopice cu forma moderata pana la severa. Dupixent este un anticorp monoclonal uman care se leaga specific de receptorul alfa al interleukinei 4 (IL-4) si inhiba semnalizarea celulara a IL4\/IL13. Dupixent a demonstrat imbunatatiri rapide si sustinute ale semnelor si simptomelor DA precum si a calitatii vietii la adulti cu DA moderat-severa. Dupixent a demonstrate un profil de siguranta favorabil la adulti cu DA moderat-severa.<\/p>\n
English version<\/span>
<\/span><\/span><\/p>\nAtopic Dermatitis is an inflammatory chronic disease, characterized by intense pruritus and eczematous lesions, it is not just an intermittent skin disease as it was considered in the past. The root cause of atopic dermatitis is Type 2\/Th 2 inflammation and IL4 and IL3 are the main cytokines involved in the immune mechanism.
Dupixent is the first approved biological therapy for the treatment of moderate to severe atopic dermatitis. Dupixent is a human monoclonal antibody that specifically binds to the alpha receptor for interleukin 4 (IL4) and inhibits the cellular signaling of IL4\/IL13. Dupixent has demonstrated rapid and sustained improvements of signs and symptoms of AD as well as quality of life in adult with moderate to severe AD. Dupixent has demonstrated a favorable safety profile in adults with moderate to severe AD.<\/p>\n
___________________________________________________________________________________________<\/p>\n
Simpozion Novartis: Terapia biologic\u0103 \u00een UCS \u2013 o solu\u021bie pentru pacient \u0219i medic!<\/span><\/p>\nSpeakers: C\u0103lin Giurc\u0103neanu1, Alin Nicolescu2<\/span><\/p>\n1Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, Bucure\u0219ti<\/span><\/p>\n2Centrul Med. de Diagnostic si Tratament\u00a0 \u201cS.R.I.\u201d<\/span><\/p>\nCuvinte cheie: omalizumab, urticarie cronic\u0103 spontan\u0103, papule, angioedem<\/p>\n
Urticaria Cronic\u0103 Spontan\u0103 este o afec\u021biune cronic\u0103 intermitent\u0103, caracterizat\u0103 prin apari\u021bia spontan\u0103 a papulelor sau\/\u0219i a angioedemului, in fiecare zi sau aproape in toate zilele, pentru cel pu\u021bin 6 s\u0103pt\u0103m\u00e2ni, f\u0103r\u0103 un stimul extern evident.<\/p>\n
Papulele \u0219i angioedemul sunt raportate in propor\u021bie de 33\u221267% la pacien\u021bii cu UCS, angioedemul singur fiind prezent doar la 1\u221213% din pacien\u021bi.
Terapia simptomatic\u0103 cu antihistaminice H1 este singura terapie de prim\u0103 inten\u021bie in UCS, dar efectul terapeutic este dovedit la mai pu\u021bin de 50 % dintre pacien\u021bii cu urticarie cronic\u0103 spontan\u0103.<\/p>\n
Omalizumab este indicat ca tratament adjuvant al UCS la pacien\u0163i adul\u0163i \u015fi adolescen\u0163i (12 ani \u0219i peste) cu r\u0103spuns neadecvat la tratamentul cu antihistaminice H1.
Doza recomandat\u0103 este de 300 mg, subcutanat, la intervale de 4 s\u0103pt\u0103m\u00e2ni.<\/p>\n
\u00cen studiile de faz\u0103 III (Asteria I, Asteria II, Glacial) omalizumab administrat in doz\u0103 de 300 mg a demonstrat \u00een mod constant \u00eembunata\u021biri semnificative ale simptomelor UCS \u00een compara\u021bie cu placebo.
Datele cumulate de siguran\u021b\u0103 din studiile de faz\u0103 III demonstreaz\u0103 c\u0103 nu au existat diferente \u00eentre grupurile de tratament \u00een ceea ce prive\u0219te inciden\u021ba evenimentelor adverse.<\/p>\n
English version<\/span><\/span><\/span><\/p>\nKeywords: omalizumab, chronic spontaneous urticaria, hives, angioedema<\/p>\n
Chronic Spontaneous Urticaria is an intermittent chronic disease, characterized by the spontaneous appearance of hives and \/ or angioedema, every day or almost every day, for at least 6 weeks, without an obvious external factor.<\/p>\n
Hives and angioedema are reported in 33\u221267% of patients with CSU, angioedema alone being present in only 1\u221213% of patients.
Symptomatic therapy with H1 antihistamines is the only first-line therapy in CSU, but the therapeutic effect is proven in less than 50% of patients with spontaneous chronic urticaria.<\/p>\n
Omalizumab is indicated as add- on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years of age and older) patients, with inadequate response to H1 antihistamines.
The recommended dose is 300 mg subcutaneously at 4-weeks intervals.<\/p>\n
In phase III studies (Asteria I, Asteria II, Glacial), Xolair consistently demonstrated significant improvements in CSU symptoms compared to placebo.
Cumulated safety data from phase III studies show that there were no differences between treatment groups in the incidence of adverse events.<\/p>\n
Scurt CV<\/span><\/p>\nPre\u015fedinte Societatea Rom\u00e2n\u0103 de Dermatologie
Medic primar dermatologie \u0219i venerologie
\u0218ef clinic\u0103 Dermato \u2013 alergologie \u0219i oncologie SUUB Elias
Membru al Academiei Europene de Dermatologie \u0219i Venerologie
Pre\u0219edinte Comisie Terapii biologice \u00een psoriazis CNAS
Universitatea de Medicin\u0103 \u0219i Farmacie \u201eCarol Davila\u201d Bucure\u0219ti<\/p>\n
Un adev\u0103rat reper al dermatologiei rom\u00e2ne\u0219ti, Prof. Dr. Calin Giurcaneanu, asigura experien\u021b\u0103 \u0219i \u00eenalt\u0103 calificare \u00een domeniul dermatovenerologiei \u0219i ofer\u0103 constant solu\u021bii eficiente \u00een diagnosticul \u0219i tratamentul afec\u021biuniilor cutanate dar \u0219i a bolilor dermatologice rare.<\/p>\n
\u00a0<\/span><\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n
![\"\"](\"https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2020\/02\/eventer_logo_150px.png\")
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464,10156,10157″ fullwidth=”on” _builder_version=”4.9.7″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Acad. Prof. Univ. Dr. C\u0103lin Giurc\u0103neanu Universitatea de Medicin\u0103 \u0219i Farmacie \u201eCarol Davila\u201d Bucure\u0219ti Simpozion Sanofi: Dupilumab \u2013 primul imunomodulator in Dermatita Atopica Speaker: C\u0103lin Giurc\u0103neanu DA este o boala inflamatorie cronica sistemica si nu doar o bolala de piele intermitenta, asa cum era considerata in trecut, caracterizata prin prurit intens si leziuni eczematoase. Adevarata […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-9798","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=9798"}],"version-history":[{"count":13,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9798\/revisions"}],"predecessor-version":[{"id":10517,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9798\/revisions\/10517"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=9798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Acad. Prof. Univ. Dr. C\u0103lin Giurc\u0103neanu
\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201eCarol Davila\u201d Bucure\u0219ti
\n<\/strong><\/span><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″ locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.7″]<\/p>\n
Simpozion Sanofi: Dupilumab \u2013 primul imunomodulator in Dermatita Atopica<\/span>
Speaker: C\u0103lin Giurc\u0103neanu<\/span><\/p>\nDA este o boala inflamatorie cronica sistemica si nu doar o bolala de piele intermitenta, asa cum era considerata in trecut, caracterizata prin prurit intens si leziuni eczematoase. Adevarata cauza a dermatitei atopice este inflamatia de Tip2\/Th2 iar IL4 si IL13 sunt citokinele cheie implicate in mecanismul imunologic.
Dupixent este prima terapie biologica aprobata pentru tratamentul dermatitei atopice cu forma moderata pana la severa. Dupixent este un anticorp monoclonal uman care se leaga specific de receptorul alfa al interleukinei 4 (IL-4) si inhiba semnalizarea celulara a IL4\/IL13. Dupixent a demonstrat imbunatatiri rapide si sustinute ale semnelor si simptomelor DA precum si a calitatii vietii la adulti cu DA moderat-severa. Dupixent a demonstrate un profil de siguranta favorabil la adulti cu DA moderat-severa.<\/p>\n
English version<\/span>
<\/span><\/span><\/p>\nAtopic Dermatitis is an inflammatory chronic disease, characterized by intense pruritus and eczematous lesions, it is not just an intermittent skin disease as it was considered in the past. The root cause of atopic dermatitis is Type 2\/Th 2 inflammation and IL4 and IL3 are the main cytokines involved in the immune mechanism.
Dupixent is the first approved biological therapy for the treatment of moderate to severe atopic dermatitis. Dupixent is a human monoclonal antibody that specifically binds to the alpha receptor for interleukin 4 (IL4) and inhibits the cellular signaling of IL4\/IL13. Dupixent has demonstrated rapid and sustained improvements of signs and symptoms of AD as well as quality of life in adult with moderate to severe AD. Dupixent has demonstrated a favorable safety profile in adults with moderate to severe AD.<\/p>\n
___________________________________________________________________________________________<\/p>\n
Simpozion Novartis: Terapia biologic\u0103 \u00een UCS \u2013 o solu\u021bie pentru pacient \u0219i medic!<\/span><\/p>\nSpeakers: C\u0103lin Giurc\u0103neanu1, Alin Nicolescu2<\/span><\/p>\n1Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, Bucure\u0219ti<\/span><\/p>\n2Centrul Med. de Diagnostic si Tratament\u00a0 \u201cS.R.I.\u201d<\/span><\/p>\nCuvinte cheie: omalizumab, urticarie cronic\u0103 spontan\u0103, papule, angioedem<\/p>\n
Urticaria Cronic\u0103 Spontan\u0103 este o afec\u021biune cronic\u0103 intermitent\u0103, caracterizat\u0103 prin apari\u021bia spontan\u0103 a papulelor sau\/\u0219i a angioedemului, in fiecare zi sau aproape in toate zilele, pentru cel pu\u021bin 6 s\u0103pt\u0103m\u00e2ni, f\u0103r\u0103 un stimul extern evident.<\/p>\n
Papulele \u0219i angioedemul sunt raportate in propor\u021bie de 33\u221267% la pacien\u021bii cu UCS, angioedemul singur fiind prezent doar la 1\u221213% din pacien\u021bi.
Terapia simptomatic\u0103 cu antihistaminice H1 este singura terapie de prim\u0103 inten\u021bie in UCS, dar efectul terapeutic este dovedit la mai pu\u021bin de 50 % dintre pacien\u021bii cu urticarie cronic\u0103 spontan\u0103.<\/p>\n
Omalizumab este indicat ca tratament adjuvant al UCS la pacien\u0163i adul\u0163i \u015fi adolescen\u0163i (12 ani \u0219i peste) cu r\u0103spuns neadecvat la tratamentul cu antihistaminice H1.
Doza recomandat\u0103 este de 300 mg, subcutanat, la intervale de 4 s\u0103pt\u0103m\u00e2ni.<\/p>\n
\u00cen studiile de faz\u0103 III (Asteria I, Asteria II, Glacial) omalizumab administrat in doz\u0103 de 300 mg a demonstrat \u00een mod constant \u00eembunata\u021biri semnificative ale simptomelor UCS \u00een compara\u021bie cu placebo.
Datele cumulate de siguran\u021b\u0103 din studiile de faz\u0103 III demonstreaz\u0103 c\u0103 nu au existat diferente \u00eentre grupurile de tratament \u00een ceea ce prive\u0219te inciden\u021ba evenimentelor adverse.<\/p>\n
English version<\/span><\/span><\/span><\/p>\nKeywords: omalizumab, chronic spontaneous urticaria, hives, angioedema<\/p>\n
Chronic Spontaneous Urticaria is an intermittent chronic disease, characterized by the spontaneous appearance of hives and \/ or angioedema, every day or almost every day, for at least 6 weeks, without an obvious external factor.<\/p>\n
Hives and angioedema are reported in 33\u221267% of patients with CSU, angioedema alone being present in only 1\u221213% of patients.
Symptomatic therapy with H1 antihistamines is the only first-line therapy in CSU, but the therapeutic effect is proven in less than 50% of patients with spontaneous chronic urticaria.<\/p>\n
Omalizumab is indicated as add- on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years of age and older) patients, with inadequate response to H1 antihistamines.
The recommended dose is 300 mg subcutaneously at 4-weeks intervals.<\/p>\n
In phase III studies (Asteria I, Asteria II, Glacial), Xolair consistently demonstrated significant improvements in CSU symptoms compared to placebo.
Cumulated safety data from phase III studies show that there were no differences between treatment groups in the incidence of adverse events.<\/p>\n
Scurt CV<\/span><\/p>\nPre\u015fedinte Societatea Rom\u00e2n\u0103 de Dermatologie
Medic primar dermatologie \u0219i venerologie
\u0218ef clinic\u0103 Dermato \u2013 alergologie \u0219i oncologie SUUB Elias
Membru al Academiei Europene de Dermatologie \u0219i Venerologie
Pre\u0219edinte Comisie Terapii biologice \u00een psoriazis CNAS
Universitatea de Medicin\u0103 \u0219i Farmacie \u201eCarol Davila\u201d Bucure\u0219ti<\/p>\n
Un adev\u0103rat reper al dermatologiei rom\u00e2ne\u0219ti, Prof. Dr. Calin Giurcaneanu, asigura experien\u021b\u0103 \u0219i \u00eenalt\u0103 calificare \u00een domeniul dermatovenerologiei \u0219i ofer\u0103 constant solu\u021bii eficiente \u00een diagnosticul \u0219i tratamentul afec\u021biuniilor cutanate dar \u0219i a bolilor dermatologice rare.<\/p>\n
\u00a0<\/span><\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464,10156,10157″ fullwidth=”on” _builder_version=”4.9.7″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Acad. Prof. Univ. Dr. C\u0103lin Giurc\u0103neanu Universitatea de Medicin\u0103 \u0219i Farmacie \u201eCarol Davila\u201d Bucure\u0219ti Simpozion Sanofi: Dupilumab \u2013 primul imunomodulator in Dermatita Atopica Speaker: C\u0103lin Giurc\u0103neanu DA este o boala inflamatorie cronica sistemica si nu doar o bolala de piele intermitenta, asa cum era considerata in trecut, caracterizata prin prurit intens si leziuni eczematoase. Adevarata […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-9798","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=9798"}],"version-history":[{"count":13,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9798\/revisions"}],"predecessor-version":[{"id":10517,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9798\/revisions\/10517"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=9798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Speaker: C\u0103lin Giurc\u0103neanu<\/span><\/p>\n
DA este o boala inflamatorie cronica sistemica si nu doar o bolala de piele intermitenta, asa cum era considerata in trecut, caracterizata prin prurit intens si leziuni eczematoase. Adevarata cauza a dermatitei atopice este inflamatia de Tip2\/Th2 iar IL4 si IL13 sunt citokinele cheie implicate in mecanismul imunologic.
Dupixent este prima terapie biologica aprobata pentru tratamentul dermatitei atopice cu forma moderata pana la severa. Dupixent este un anticorp monoclonal uman care se leaga specific de receptorul alfa al interleukinei 4 (IL-4) si inhiba semnalizarea celulara a IL4\/IL13. Dupixent a demonstrat imbunatatiri rapide si sustinute ale semnelor si simptomelor DA precum si a calitatii vietii la adulti cu DA moderat-severa. Dupixent a demonstrate un profil de siguranta favorabil la adulti cu DA moderat-severa.<\/p>\n
English version<\/span> Atopic Dermatitis is an inflammatory chronic disease, characterized by intense pruritus and eczematous lesions, it is not just an intermittent skin disease as it was considered in the past. The root cause of atopic dermatitis is Type 2\/Th 2 inflammation and IL4 and IL3 are the main cytokines involved in the immune mechanism. ___________________________________________________________________________________________<\/p>\n Simpozion Novartis: Terapia biologic\u0103 \u00een UCS \u2013 o solu\u021bie pentru pacient \u0219i medic!<\/span><\/p>\n Speakers: C\u0103lin Giurc\u0103neanu1, Alin Nicolescu2<\/span><\/p>\n 1Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, Bucure\u0219ti<\/span><\/p>\n 2Centrul Med. de Diagnostic si Tratament\u00a0 \u201cS.R.I.\u201d<\/span><\/p>\n Cuvinte cheie: omalizumab, urticarie cronic\u0103 spontan\u0103, papule, angioedem<\/p>\n Urticaria Cronic\u0103 Spontan\u0103 este o afec\u021biune cronic\u0103 intermitent\u0103, caracterizat\u0103 prin apari\u021bia spontan\u0103 a papulelor sau\/\u0219i a angioedemului, in fiecare zi sau aproape in toate zilele, pentru cel pu\u021bin 6 s\u0103pt\u0103m\u00e2ni, f\u0103r\u0103 un stimul extern evident.<\/p>\n Papulele \u0219i angioedemul sunt raportate in propor\u021bie de 33\u221267% la pacien\u021bii cu UCS, angioedemul singur fiind prezent doar la 1\u221213% din pacien\u021bi. Omalizumab este indicat ca tratament adjuvant al UCS la pacien\u0163i adul\u0163i \u015fi adolescen\u0163i (12 ani \u0219i peste) cu r\u0103spuns neadecvat la tratamentul cu antihistaminice H1. \u00cen studiile de faz\u0103 III (Asteria I, Asteria II, Glacial) omalizumab administrat in doz\u0103 de 300 mg a demonstrat \u00een mod constant \u00eembunata\u021biri semnificative ale simptomelor UCS \u00een compara\u021bie cu placebo. English version<\/span><\/span><\/span><\/p>\n Keywords: omalizumab, chronic spontaneous urticaria, hives, angioedema<\/p>\n Chronic Spontaneous Urticaria is an intermittent chronic disease, characterized by the spontaneous appearance of hives and \/ or angioedema, every day or almost every day, for at least 6 weeks, without an obvious external factor.<\/p>\n Hives and angioedema are reported in 33\u221267% of patients with CSU, angioedema alone being present in only 1\u221213% of patients. Omalizumab is indicated as add- on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years of age and older) patients, with inadequate response to H1 antihistamines. In phase III studies (Asteria I, Asteria II, Glacial), Xolair consistently demonstrated significant improvements in CSU symptoms compared to placebo. Scurt CV<\/span><\/p>\n Pre\u015fedinte Societatea Rom\u00e2n\u0103 de Dermatologie Un adev\u0103rat reper al dermatologiei rom\u00e2ne\u0219ti, Prof. Dr. Calin Giurcaneanu, asigura experien\u021b\u0103 \u0219i \u00eenalt\u0103 calificare \u00een domeniul dermatovenerologiei \u0219i ofer\u0103 constant solu\u021bii eficiente \u00een diagnosticul \u0219i tratamentul afec\u021biuniilor cutanate dar \u0219i a bolilor dermatologice rare.<\/p>\n \u00a0<\/span><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n Contacteaz\u0103 operatorul PDI 2021<\/p>\n [\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n Operatorul PDI 2021<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n <\/span><\/p>\n <\/span><\/p>\n Adresa: Str. A. Panu nr. 13, Iasi<\/span> [\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n Parteneri Media<\/p>\n [\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464,10156,10157″ fullwidth=”on” _builder_version=”4.9.7″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Acad. Prof. Univ. Dr. C\u0103lin Giurc\u0103neanu Universitatea de Medicin\u0103 \u0219i Farmacie \u201eCarol Davila\u201d Bucure\u0219ti Simpozion Sanofi: Dupilumab \u2013 primul imunomodulator in Dermatita Atopica Speaker: C\u0103lin Giurc\u0103neanu DA este o boala inflamatorie cronica sistemica si nu doar o bolala de piele intermitenta, asa cum era considerata in trecut, caracterizata prin prurit intens si leziuni eczematoase. Adevarata […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-9798","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=9798"}],"version-history":[{"count":13,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9798\/revisions"}],"predecessor-version":[{"id":10517,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9798\/revisions\/10517"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=9798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/span><\/span><\/p>\n
Dupixent is the first approved biological therapy for the treatment of moderate to severe atopic dermatitis. Dupixent is a human monoclonal antibody that specifically binds to the alpha receptor for interleukin 4 (IL4) and inhibits the cellular signaling of IL4\/IL13. Dupixent has demonstrated rapid and sustained improvements of signs and symptoms of AD as well as quality of life in adult with moderate to severe AD. Dupixent has demonstrated a favorable safety profile in adults with moderate to severe AD.<\/p>\n
Terapia simptomatic\u0103 cu antihistaminice H1 este singura terapie de prim\u0103 inten\u021bie in UCS, dar efectul terapeutic este dovedit la mai pu\u021bin de 50 % dintre pacien\u021bii cu urticarie cronic\u0103 spontan\u0103.<\/p>\n
Doza recomandat\u0103 este de 300 mg, subcutanat, la intervale de 4 s\u0103pt\u0103m\u00e2ni.<\/p>\n
Datele cumulate de siguran\u021b\u0103 din studiile de faz\u0103 III demonstreaz\u0103 c\u0103 nu au existat diferente \u00eentre grupurile de tratament \u00een ceea ce prive\u0219te inciden\u021ba evenimentelor adverse.<\/p>\n
Symptomatic therapy with H1 antihistamines is the only first-line therapy in CSU, but the therapeutic effect is proven in less than 50% of patients with spontaneous chronic urticaria.<\/p>\n
The recommended dose is 300 mg subcutaneously at 4-weeks intervals.<\/p>\n
Cumulated safety data from phase III studies show that there were no differences between treatment groups in the incidence of adverse events.<\/p>\n
Medic primar dermatologie \u0219i venerologie
\u0218ef clinic\u0103 Dermato \u2013 alergologie \u0219i oncologie SUUB Elias
Membru al Academiei Europene de Dermatologie \u0219i Venerologie
Pre\u0219edinte Comisie Terapii biologice \u00een psoriazis CNAS
Universitatea de Medicin\u0103 \u0219i Farmacie \u201eCarol Davila\u201d Bucure\u0219ti<\/p>\n<\/span><\/p>\n
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n